^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH1 mutation

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
    Entrez ID:
    3417
    Related biomarkers:
    Expression
    Mutation
    Others
    Related tests:
    5d
    Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysis. (PubMed, Blood Adv)
    This review compared the efficacy and safety of low-dose cytarabine (LDAC), azacitidine (AZA), 5- and 10-day decitabine (DEC), and gemtuzumab ozogamicin, alone or combined with drugs such as venetoclax (VEN), in older adults with AML ineligible for conventional chemotherapy. Treatment decisions should consider patient goals and functional status. These findings informed eight recommendations in updated ASH-AML guidelines.
    Retrospective data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • decitabine • Mylotarg (gemtuzumab ozogamicin)
    5d
    Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How? (PubMed, J Gastrointest Cancer)
    Molecular testing has become an essential component of modern iCCA management. Broad, early, and technically integrated molecular profiling-ideally performed at initial diagnosis and interpreted in an interdisciplinary (molecular) tumor board-is critical to fully realize the potential of precision oncology in BTC.
    Review • Journal • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • HER-2 amplification • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion
    7d
    Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells. (PubMed, Nat Chem Biol)
    Interestingly, C269 autopalmitoylation occurs within a hydrophobic pocket, targeted by a clinical IDH1-mutant inhibitor (LY3410738). Our study reveals that autopalmitoylation, conferred by the IDH1R132H mutation, links fatty acid metabolism to the regulation of IDH1 mutant activity and represents a druggable vulnerability in IDH1-mutant cancers.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type • IDH1 R132
    |
    LY3410738
    8d
    Characteristics of auditory event-related potential and prediction of IDH1 mutation in patients with insular glioma. (PubMed, Quant Imaging Med Surg)
    The IDH1-wt group showed higher amplitude of MMN evoked by novel stimulus at Fz and Cz and longer latency of the P300 component evoked by a deviant stimulus at Fz. The combination of AERP parameters yielded a more effective means to predict IDH1 mutation status in patients with insular glioma, which may provide guidance for the surgical intervention of this disease.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type
    |
    Akeega (abiraterone/niraparib)
    10d
    Actionable Genomic Landscape of Biliary Tract Cancer in the Indian Population. (PubMed, Oncologist)
    This study provides a comprehensive molecular profiling of BTCs in the Indian population, revealing key genomic alterations, subtype-specific differences, and associations with immune features. The findings underscore the importance of molecular profiling in guiding personalized treatment strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • KRAS mutation • HER-2 amplification • PIK3CA mutation • IDH1 mutation • ARID1A mutation • STK11 mutation • PD-L1 negative
    10d
    Multiplexed Data-Independent Acquisition (mDIA) to Profile Extracellular Vesicle Proteomes. (PubMed, Mol Cell Proteomics)
    Results showed that library-based DIA, with project-specific spectral libraries generated from StageTip-based fractionation, outperformed other pipelines in protein identification and quantification. We demonstrated for the first time EV proteome landscape changes caused by the IDH1 mutation and inhibitor treatment in intrahepatic cholangiocarcinoma, highlighting the utility of mDIA in EV-based biomarker discovery.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Tibsovo (ivosidenib)
    10d
    Molecular Characterization of Adult-Type Lower-Grade Glioma (WHO Grade 1-3) with Targeted Next-Generation Sequencing: A Retrospective, Single-Institution Experience. (PubMed, J Clin Med)
    Despite the exploratory nature of the analysis on a small population, the study underscores the biological and transcriptional heterogeneity of LGGs and highlights the limitations of tumor-only sequencing approaches. Broader genomic profiling and matched normal controls are warranted to refine the interpretation of rare or non-canonical variants.
    Retrospective data • Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • IDH1 mutation • MET amplification • EGFR amplification • MYCN amplification • IDH wild-type
    |
    TruSight Oncology 500 Assay
    10d
    Differences in Executive Functioning Between Patients with IDH1-Mutant Oligodendroglioma and Astrocytoma Before and After Surgery. (PubMed, Cancers (Basel))
    Specific aspects of executive functioning in IDH1-mutant gliomas may differ by subtype. Oligodendroglioma patients showed postoperative decline in cognitive flexibility that did not recover to baseline level, particularly in case of surgery under general anesthesia. These results highlight the potential relevance of tumor subtype and surgical approach in limiting cognitive risks after glioma surgery.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    12d
    IDH1-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism. (PubMed, Haematologica)
    Not available.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    21d
    Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. (PubMed, Clin Lymphoma Myeloma Leuk)
    Olutasidenib-based therapy demonstrated 100% response rates in previously untreated IDH1-mutated AML and MDS and modest efficacy in heavily pretreated R/R AML and MDS. Durable remissions occurred in select responders and with stem cell transplant. Further evaluation of olutasidenib as frontline therapy in IDH1-mutated AML or MDS and as a bridge to transplant is warranted.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • Tibsovo (ivosidenib) • Rezlidhia (olutasidenib)